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Introduction
Idiosyncratic drug reactions are adverse responses that occur in a small fraction of people taking a drug, and the liver is a frequent target organ. The unpredictable nature and severity of idiosyncratic liver injury have significant impact both on human health and the pharmaceutical industry. Although numerous studies have proposed that idiosyncratic hepatotoxicity occurs as a consequence of metabolic polymorphism and/or drug-specific immunity (for reviews see Ju and Uetrecht, 2002; Pirmohamed et al., 1996) , for the vast majority of drugs the mechanisms underlying idiosyncratic responses are unclear. Recent studies have suggested that an inflammatory response might precipitate idiosyncratic liver injury from some drugs, and animal models have been developed to examine drug-inflammation interaction (Buchweitz et al., 2002; Luyendyk et al., 2003b; Roth et al., 2003) . In a separate group of rats, animals were treated heparin (3000 U/kg, s.c.) or sterile saline 1 h after LPS administration then given FAM or RAN as described above. Rats were anesthetized 2 or 6 h later as above for evaluation of hepatic gene expression (2 h) and hepatocellular injury (2 and 6 h). Gene expression was evaluated at the time of onset of hepatocellular injury (2 h) so that changes could be associated with the pathogenesis. Another group of animals was killed at 6 h to confirm the occurrence of liver injury.
Sample collection. Blood drawn from the dorsal aorta was collected rapidly in BD Vacutainer
TM Plus Plastic Citrate Tubes (Becton-Dickinson, Franklin Lakes, NJ) or allowed to clot at room temperature. Citrated-plasma and serum were collected and aliquots stored at -80˚ C until use. Three, 100 mg midlobe pieces of the right medial liver lobe were flash-frozen in liquid nitrogen for RNA isolation. Slices (3-4 mm thick) of the ventral portion of the left lateral lobe were collected and fixed in 10% neutral buffered formalin.
JPET #96305 measures total PAI-1 (i.e., active, inactive and tissue plasminogen activator/PAI-1-complexed forms). Plasma fibrinogen was determined from thrombin clotting time of diluted samples using a fibrometer and a commercially available kit (B4233) from Dade-Behring, Inc. (Deerfield, IL).
Plasma thrombin-antithrombin (TAT) concentration was determined using ELISA kit #OWMG15 from Dade-Behring.
RNA isolation and purification. Total RNA was isolated from a small piece of frozen liver tissue using Trizol  (Invitrogen Corporation, Carlsbad, CA) and purified using RNeasy spin columns (Qiagen, Valencia, CA) according to the manufacturers' instructions. Complete removal of DNA was achieved by using a Qiagen's RNase-Free DNase Set. The quality of the RNA was evaluated by measuring the 260:280 nm absorbance ratio, and the integrity of 18S and 28S ribosomal RNA bands was assessed by electrophoresis on RNA 6000 Nano labchips (Agilent Technologies, Palo Alto, CA). RNA concentrations were determined from absorbance values at a wavelength of 260 nm using a SpectraMax spectrophotometer (Molecular Devices Corporation, Sunnyvale, CA).
Probe preparation and microarray hybridization. Sample labeling, hybridization, and staining were carried out according to the Eukaryotic Target Preparation protocol in the Affymetrix® Technical Manual for GeneChip® Expression Analysis. In summary, 5 µ g of purified total RNA was used to generate double-stranded cDNA using Superscript reverse transcriptase (Invitrogen Life Technologies) and a T7-oligo (dT) primer. The resulting cDNA was purified using the GeneChip Sample Cleanup Module according to the manufacturer's protocol. The purified cDNA was amplified using BioArray high yield RNA transcription labeling kit (Enzo) according to the manufacturer's instructions to produce biotin-labeled cRNA (complementary RNA) which was then purified using GeneChip Sample Cleanup Module and This article has not been copyedited and formatted. The final version may differ from this version. Biosoftware, Seattle, WA). Intrachip normalization and background corrections were applied to the hybridizations or profiles, and the replicate profiles were combined in an error-weighted fashion to create ratio experiments with each treatment group as the baseline. Interchip scaling was done to normalize intensity brightness, both across multiple microarrays of the same pattern and of different patterns. Error-model-based transformation was then applied to intensity profiles, and the transformed data were corrected for nonlinearity of expression levels. Errorweighted ANOVA was performed on the input data that were partitioned into groups (ratio experiments) to determine whether any statistically significant differences existed among the group means. Genes were considered active if p<0.01 and the fold change for a comparison was at least +/-1.5-fold compared to Veh/Veh-treated rats. Clustering analysis was performed using an agglomerative hierarchical clustering algorithm where error-weighted Euclidean distancebased measure (emphasizes the magnitude of the fold changes based on the sum of squares of differences in each direction) was used as similarity measurement.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Effect of RAN or FAM cotreatment on LPS-induced coagulation system activation.
Rats were given either LPS or its vehicle and cotreated with RAN, FAM-EE, FAM-EM, or Veh.
Coagulation system activation was estimated 2 h after drug administration from the decrease in plasma fibrinogen and from an increase in plasma TAT concentration. Plasma fibrinogen concentration decreased (Fig. 1A ) and plasma TAT concentration increased (Fig. 1B) after LPS treatment, irrespective of drug cotreatment. Confirming previous results (Luyendyk et al., 2004a) , RAN cotreatment caused an additional increase in plasma TAT concentration (Fig 1A and 1B) . Treatment with RAN alone caused a decrease in plasma fibrinogen (Fig. 1A) .
Consumption of fibrinogen after treatment with RAN was not associated with significantly increased TAT concentration (Fig. 1B) . FAM did not cause any of the changes in the coagulation system imposed by RAN.
Effect of anticoagulation on hepatotoxicity after LPS/RAN-cotreatment. Since neither FAM-EE nor FAM-EM treatments augmented LPS-induced coagulation system activation, the more pharmacologically comparable dose (i.e., FAM-EE) was selected for studies to evaluate the effect of anticoagulation on gene expression. As depicted in Fig 1A , LPS administration caused a significant decrease in plasma fibrinogen concentration. LPS/RANcotreatment caused a more pronounced decrease in plasma fibrinogen compared to LPS/Vehtreated rats, whereas FAM cotreatment had no further effect. Coadministration of heparin significantly attenuated this decrease in both LPS/FAM and LPS/RAN-cotreated rats at 2 and 6 h ( Fig. 2A) . Confirming previous results (Luyendyk et al., 2003b) , LPS/RAN cotreatment, but not LPS/FAM cotreatment, caused a significant increase in serum ALT activity (normal ~50 U/L) at 2 h that became more pronounced by 6 h ( LPS/Veh/RAN-treated rats by 2 h and was more prevalent (6 of 7) at 6h. Consistent with the reduction in ALT activity, heparin prevented these changes completely at 2 h and markedly reduced the prevalence (1 of 5 rats) at 6 h ( Table 2) . 
Effect of heparin on LPS/RAN-induced gene expression. Two criteria were
established to identify individual genes that had the potential to be mechanistically relevant to LPS/RAN-induced liver injury and that were regulated by coagulation system activation.
Inasmuch as hepatocellular injury occurred in LPS/Veh/RAN-but not LPS/Veh/FAM-treated rats, we first identified genes expressed to a different degree in these groups as those that might be mechanistically relevant to the injury. Accordingly, probesets for which gene expression was different in LPS/Veh/RAN-treated rats relative to LPS/Veh/FAM-treated rats were first selected (i.e., Criterion A). This group of probesets, denoted as set A, is listed in Supplemental Table 1 .
Next, probesets were identified for which heparin coadministration altered expression in LPS/RAN-treated rats (Criterion B). Heparin altered the expression of 145 probesets in LPS/RAN-treated rats (Supplemental Table 2 ). Probesets that met both criteria were denoted subset AB and are listed in Supplemental Table 3 , and those with annotation currently available are shown in Table 3 . The AB set contains only twenty nine probesets (Supplemental Table 3) This article has not been copyedited and formatted. The final version may differ from this version. and annotation was available for 15 (Table 3) . These genes are perhaps the most interesting because they distinguish the drug treatment that produces hepatocellular injury from one that does not, and an agent that reduces injury in LPS/RAN-treated rats (i.e., heparin) prevents or reduces their expression. These included several genes encoding products involved in inflammation (i.e., Csf3, Cxcl2, IL6, Ptgs2, Gzmb), in transporting agents across membranes (i.e., Atp1b1, Slc5a3), and signal transduction (i.e., Stk2, Rac1, Klf4). Many of them were also associated with hypoxia (Atp1b1, Egln3, Cxcl2, Ptgs2, Rac1, Tfrc; Table 3 ).
Some gene products were changed in LPS-treated rats by RAN coexposure but not by FAM cotreatment and were, in addition, not affected by heparin (ie, met criterion A but not B).
These might be important for LPS/RAN-induced liver injury, but the cause of their altered expression is unrelated to activation of the coagulation system. This subset was denoted A.1 and is shown in Supplemental Table 3 . This group included PAI-1, egr-1, and btg2, three genes expressed to a greater degree in rats treated with LPS/RAN compared to treatment with RAN or LPS alone (Luyendyk et al., 2004b) .
Real-time PCR. Real-time PCR was used to verify selected gene expression changes observed from microarray analysis. Four genes (PAI-1, BNIP3, Atf3, MAPKAPK-2) from the A.1 subset (Fig. 4 ) and 3 genes from the AB subset (COX-2, Cxcl2 [MIP-2], IL-6) were selected for confirmation (Fig. 5) . The expression of PAI-1, BNIP3, and MAPKAPK-2, was greater (1.6-fold, 2-fold, 1.6-fold, respectively) in LPS/Veh/RAN-treated rats compared to LPS/Veh/FAMtreated rats, and the expression of each gene was not significantly affected by heparin coadministration in any treatment group (Fig. 4A , B, C). The expression of Atf3 was greater (3-fold) in LPS/Veh/RAN-treated rats compared to LPS/Veh/FAM-treated rats and was This article has not been copyedited and formatted. The final version may differ from this version. significantly reduced by heparin (Fig. 4D) . However, heparin did not reduce Atf3 expression to that observed after LPS/heparin/FAM treatment.
The expression of Ptgs2 (i.e., COX-2, cyclooxygenase-2) was greater (2.3-fold) in LPS/Veh/RAN-treated rats compared to LPS/Veh/FAM-treated rats (Fig. 5A) . Heparin was without effect in LPS/FAM-treated rats but prevented the enhanced expression of COX-2 in LPS/RAN-treated rats (Fig. 5A ). Cxcl2 (MIP-2, macrophage inflammatory protein-2) expression was greater (2-fold) in LPS/Veh/RAN-treated rats compared to LPS/Veh/FAM-treated rats.
Heparin was without effect on MIP-2 in LPS/FAM-treated rats but prevented its enhanced expression in LPS/RAN-treated rats (Fig. 5B) . Expression of the inflammatory cytokine IL-6 (i.e., interleukin-6) mRNA was greater (1.8-fold) in LPS/Veh/RAN-treated rats compared to LPS/Veh/FAM-treated rats (Fig. 5C ), and this increase was prevented by heparin administration.
Effect of heparin on serum MIP-2 concentration. MIP-2 is a PMN chemokine, and its
upregulation is of interest since LPS/RAN hepatotoxicity depends on PMNs (Luyendyk et al., 2005b) . The concentration of MIP-2 in serum of naïve rats was ~20 pg/ml (data not shown). 2h
after RAN administration, serum MIP-2 concentration increased markedly in LPS-treated rats, but this increase was much greater after RAN cotreatment (39 ng/ml; Fig. 6 ) than after FAM cotreatment (18 ng/ml). Consistent with its reduction in MIP-2 gene expression at 2 h, heparin reduced serum MIP-2 concentration in LPS/RAN-treated rats at both 2 and 6 h, but it was without a statistically significant effect in LPS/FAM-treated rats (Fig. 6 ). Despite this overall decrease, serum MIP-2 concentration remained elevated in LPS/Veh/RAN-treated rats compared to LPS/Veh/FAM-treated rats.
Effect of heparin on serum PAI-1 concentration. An earlier study showed that serum PAI-1 was increased by LPS treatment and that this increase was markedly enhanced by This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 7) to a value similar to that seen in rats treated only with LPS (data not shown). In striking contrast, heparin significantly increased PAI-1 concentration in LPS/FAM-treated rats (Fig. 7) . In a separate timecourse study, the LPS/RANinduced increase in serum PAI-1 concentration was reduced by heparin at both 3 and 6 h by more than 50% (data not shown).
Discussion
Previous studies demonstrated that LPS/RAN-cotreatment, but not LPS/FAMcotreatment, results in hepatocellular injury, and that anticoagulation attenuates injury in this model (Luyendyk et al., 2003b; Luyendyk et al., 2004a) . Treatment with RAN alone decreased fibrinogen concentration without a corresponding activation of thrombin, suggesting a thrombinindependent consumption of fibrinogen (Fig. 1) . Interestingly, a similar effect was not observed in rats given FAM alone, suggesting that this effect is unique to RAN. The enzyme responsible for this decrease has not yet been identified, but it is known that other enzymes, including metalloproteinases, can degrade fibrinogen (Bini et al., 1996) .
Treatment with LPS alone caused an increase in TAT and a decrease in plasma fibrinogen concentration that were augmented by RAN cotreatment but not FAM-cotreatment ( Fig. 1 and 2A ). Since heparin attenuated coagulation system activation and hepatocellular injury in LPS/RAN-treated rats (Fig. 2, Table 2 ), these results suggest that enhanced thrombin generation as well as hepatocellular injury are specific to LPS/RAN-cotreatment and independent of H2-receptor antagonism.
The effect of anticoagulation on hepatic gene expression in LPS/RAN-and LPS/FAMtreated rats was examined at a time near the onset of hepatocellular injury, thereby minimizing the likelihood that a reduction in gene expression by heparin is a consequence of lessened injury.
Hierarchical clustering distinguished LPS/RAN and LPS/FAM groups but did not distinguish heparin-cotreated rats from those cotreated with Veh (Fig. 3) . This indicates that, despite its near complete reduction of hepatocellular injury, heparin altered the expression of a small number of genes in LPS/RAN rats (i.e., only ~0.5% of probesets). However, heparin changed even fewer probesets in LPS/FAM-treated rats (~0.06%), a result consistent with heparin altering gene expression only in association with the treatment that caused pronounced hepatic coagulation system activation (Fig. 1) . Coagulation system activation might cause injury by altering expression of one or more of the relatively few gene products that were affected in LPS/RANtreated rats. Alternatively, the protective effect of heparin in this model might be independent of changes in gene expression.
Several probesets were differentially expressed in LPS/RAN-cotreated rats compared to LPS/FAM-treated rats. These gene products are of obvious potential mechanistic interest, since liver injury occurred only in LPS/RAN-treated rats. To determine whether for any of these genes the difference was mediated by the coagulation system, their expression was compared after heparin coadministration, and two subsets were generated: 1) subset A.1: LPS/Veh/RAN different from LPS/Veh/FAM, but not different from LPS/heparin/RAN (i.e., genes met criteria A, but not B, Supplemental Table 3 ) and 2) subset AB: LPS/Veh/RAN different from LPS/Veh/FAM and different from LPS/heparin/RAN (i.e., genes met both criterion A and B, Supplemental Table 3 ). Gene products comprising the A.1 subset might be important for LPS/RAN-induced liver injury but were unaffected by heparin, suggesting that their differential expression is independent of coagulation system activation. Real-time PCR confirmed that heparin did not prevent LPS/RAN-mediated expression of genes encoding PAI-1, BNIP3, and MAPKAPK-2 (Fig. 5 ). In the case of Atf3, real-time PCR indicated an attenuation of Atf3 expression by heparin, suggesting that Atf3 should actually be segregated to the AB subset.
PAI-1 is one of the genes in the A.1 subset that has received attention in the LPS/RANmodel due to the importance of fibrin clots and tissue hypoxia (Luyendyk et al., 2004a) . In LPS/RAN-treated rats, heparin treatment reduced both sinusoidal fibrin deposition and liver hypoxia (Luyendyk et al., 2004a; Luyendyk et al., 2005b LPS/RAN-treated rats, suggesting that enhanced expression of PAI-1 mRNA in LPS/RANtreated rats occurs through a hemostasis-independent mechanism. Since heparin also markedly reduces hypoxia in livers of LPS/RAN-treated rats, PAI-1 mRNA expression appears to be independent of hypoxia as well. Interestingly, although heparin did not affect the enhanced PAI-1 mRNA expression, it reduced the increase in serum PAI-1 protein concentration (Fig. 7) . One potential source of PAI-1 is platelets, which release preformed PAI-1 upon stimulation with thrombin (Brogren et al., 2004) . Taken together, the data indicate that enhanced PAI-1 appearance in LPS/RAN-treated rats is mediated through both transcription-dependent andindependent mechanisms, the latter occurring during coagulation.
Unexpectedly, in LPS/FAM-treated rats heparin increased serum PAI-1 concentration, but not hepatic expression of PAI-1 mRNA (Fig. 7) . The mechanism causing this increase is not clear, but it might be a response to excessive anticoagulation. Whereas LPS-induced coagulation and plasma PAI-1 concentration were enhanced by RAN cotreatment, FAM lacked these effects.
Anticoagulation in LPS/RAN-treated rats reduced serum PAI-1 and liver injury, whereas anticoagulation in uninjured LPS/FAM-treated rats might have increased PAI-1 as a compensatory response to "rebalance" the hemostastic system. Whether or not this effect of FAM on PAI-1 concentration resulted from H2-receptor antagonism is currently unknown.
Regardless, the effect of heparin on PAI-1 in LPS/FAM-treated rats is likely not relevant to the mechanism of injury, since injury did not occur in these rats.
This article has not been copyedited and formatted. The final version may differ from this version. Genes comprising the AB subset are potentially related to the mechanism by which the coagulation system contributes to LPS/RAN-induced liver injury, since heparin prevented the difference in expression between LPS/RAN and LPS/FAM groups. This gene subset contained several hypoxia-inducible genes, consistent with the reduction in liver hypoxia by heparin in this model (Luyendyk et al., 2005b) . Indeed, the expression of several of these, (i.e., Atp1b1, Cxcl2, Egln3, ptgs2, and tfrc) as well as genes involved in hypoxic signaling (i.e., Rac1) was prevented by heparin. However, several hypoxia-inducible genes were also identified in the A.1 subset (e.g., BNIP3, egr-1, PAI-1), suggesting that their expression occurred by hypoxia-independent factors. All of these genes are likely controlled by several transcription factors activated by numerous initiators of intracellular signaling, one of which is hypoxia. For example, induction of egr-1 expression is regulated by hypoxia and inflammatory cytokines (Yan et al., 1999; Cao et al., 1992) , both of which are enhanced in LPS/RAN-treated rats. Additional studies are required to determine the relative contributions of inflammatory mediators and hypoxia to their regulation.
One gene product in subset AB for which regulation by hypoxia might be important is Coagulation system activation also appears to be critical for enhanced expression of the COX-2 gene in LPS/RAN-treated rats (Fig. 5) . Coagulation-mediated COX-2 (ptgs2) expression might result in the production of cytotoxic lipid mediators, some of which alter hepatocellular cell death signaling pathways (Ganey et al., 2001; Maddox et al., 2004) . In a previous study, LPS-inducible COX-2 expression was enhanced by RAN, but not FAM cotreatment (Luyendyk et al., 2005a) . Similarly, coagulation system activation was enhanced in LPS-treated rats by RAN, but not FAM cotreatment (Fig. 1) . Events that occur during coagulation system activation, This article has not been copyedited and formatted. The final version may differ from this version. In summary, in our attempt to develop animal models that mimic human idiosyncratic adverse drug reactions (ADRs), we have compared a drug (i.e., RAN) that causes human ADRs with one in the same pharmacologic class that does not share this liability (i.e., FAM). We have confirmed in this study that RAN interacts with LPS to cause liver injury whereas FAM does not. A new finding was that FAM does not share RAN's ability to enhance coagulation system activation in LPS-treated rats. Another novel and somewhat surprising finding was that, despite nearly eliminating hepatocellular injury, heparin affected very few genes that were selectively altered in expression in LPS/RAN-treated rats. This finding will help to focus on certain genes for further evaluation. For example, both mRNA and protein for MIP-2 were selectively elevated in livers and serum, respectively, of LPS/RAN-treated rats, and this elevation was prevented by heparin. Like MIP-2, COX-2 mRNA was differentially expressed in LPS/RAN-cotreated rats as was the inflammatory cytokine IL-6, and these changes were reduced by heparin. PAI-1 mRNA expression was also elevated in livers of LPS/RAN-, but not LPS/FAM-treated rats; however, in this case heparin did not prevent the increase. Interestingly, heparin did reduce the increase in PAI-1 protein in plasma, suggesting that PAI-1 is released in part from a preformed pool, Rats were treated with 44.4 X 10 6 EU/kg LPS, then one hour later with heparin (3000 U/kg) or vehicle. One hour later rats were given either 30 mg/kg RAN or 6 mg/kg FAM (FAM). Two hours after drug administration, RNA was isolated from liver, and gene expression was evaluated by Affymetrix 230 2.0 Gene Array. RNA from each rat was analyzed using a separate array.
This article has not been copyedited and formatted. The final version may differ from this version. Affymetrix probesets determined to be active by a statistical filter were subjected to two-way agglomerative hierarchical clustering performed using an unweighted average and Euclidean distance as the similarity measure. This article has not been copyedited and formatted. The final version may differ from this version. Table 2 Histopathologic evaluation of liver necrosis
Rats were treated with 44.4 X 10 6 EU/kg LPS, then one hour later with heparin (3000 U/kg) or vehicle. One hour later rats were given either 30 mg/kg RAN or 6 mg/kg FAM (FAM). Livers were removed 2 or 6 h after drug treatment, fixed in 10% neutral buffered formalin, and evaluated by light microscopy. Midzonal hepatic necrosis was assigned a histopathology score as described in Materials and Methods based on the following scale: 0, no significant lesion; 1, minimal; 2, mild; 3, moderate; 4, marked; 5, severe. No livers were assigned a score >2. n=5-8 rats per group. Data are expressed as the number and % of animals in each group given each score.
This article has not been copyedited and formatted. The final version may differ from this version. Table 3 Differentially expressed genes regulated by coagulation system activation in LPS/RAN-treated rats .
Genes that met both criterion A and criterion B were identified as described in Materials and
Methods. For each comparison, the ratio of the expression signals is shown. Genes are listed alphabetically. Genes were classified based on the relationship of their gene product to one or more functions potentially relevant to LPS/RAN-induced liver injury. Genes in this group that could not be classified or were ESTs are listed in Supplemental Table 3 .
